/Investor DB

Cherubic Ventures — 2024 Investments

3 investments dated 2024 · listed companies and verified rows first · show all

Formation Bioformation.bioin𝕏May 2024

Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesSaaSNew York, US

Ben Liu(CEO & Co-Founder)inLinhao Zhang(Co-Founder)inBenjamine Liu(Founder)Kit Dobyns(Founder)Mary Rozenman(Founder)

BoardAlfred Lin(Director)in

Co-investorsAndreessen HorowitzSequoia CapitalSam AltmanSection 32Thrive CapitalFelicis Ventures+11 more

ResistanceBioresistance.bioinSeed · Jan 2024Defunct

ResistanceBio develops treatments to address drug resistance in cancer patients.

BiotechHealthtechSan Francisco, US

Nicholas Goldner(CEO)inChristopher Bulow(Founder)inKYLE LAPHAM(Executive Officer, Director)

BoardOMRI AMIRAV-DRORY(Director)in

Co-investorsAlumni VenturesFifty YearsY CombinatorAsymmetry VenturesBrightstone Venture CapitalCantos Ventures+11 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Beaubble

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.